title: Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin.
abstract: At diagnosis 10-25% of patients with colorectal liver metastases (CRLM) present as resectable disease. Liver resection is the gold standard treatment, resulting in a 5-year overall survival (OS) of 22-58%, local recurrence rates of 1.2-10.4% and a perioperative mortality of less than 5%. Multiple attempts have been made to assess the possible contribution of radiofrequency ablation (RFA) to improve OS and progression-free survival (PFS) in patients with unresectable colorectal liver metastases. The aim of this paper is to review the RFA literature in the setting of colorectal liver metastases: RFA with and without chemotherapy, RFA with and without resection, RFA for solitary unresectable CRLM, surgical and percutaneous imaging-guided RFA, RFA compared with chemotherapy. The reported OS, PFS, local recurrence rates, morbidity and mortality in these different settings are analyzed. This paper reflects on a possible role of RFA in resectable CRLM.
authors: Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands. daphnehompes@yahoo.com
authors: D
authors: D
authors: Hompes
authors: W
authors: W
authors: Prevoo
authors: T
authors: T
authors: Ruers
mesh_terms: D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D006801:Humans; D008099:Liver / Q000601:surgery*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery*; D016896:Treatment Outcome